<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01628029</url>
  </required_header>
  <id_info>
    <org_study_id>2012-0120</org_study_id>
    <secondary_id>NCI-2012-01352</secondary_id>
    <secondary_id>2012-0120</secondary_id>
    <nct_id>NCT01628029</nct_id>
  </id_info>
  <brief_title>Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer</brief_title>
  <official_title>Multimodal Therapy for the Treatment of Sleep Disturbance in Patients With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well cognitive behavioral therapy and multimodal&#xD;
      therapy works in treating sleep disturbance in patients with cancer. Cognitive behavioral&#xD;
      therapy may help reduce sleep disturbances, fatigue, and insomnia as well as improve the&#xD;
      well-being and quality of life of patients with cancer when given together with&#xD;
      methylphenidate hydrochloride, therapeutic melatonin, and light therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To obtain preliminary estimates of the effects of cognitive behavioral therapy (CBT) and&#xD;
      various treatments (light therapy, melatonin, methylphenidate [methylphenidate&#xD;
      hydrochloride]) and combinations of treatments in multimodal therapy (MMT) in reducing sleep&#xD;
      disturbance in patients with cancer, as measured by change in Pittsburgh Sleep Quality Index&#xD;
      (PSQI) scores taken at baseline and on day 15.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To explore the effect of MMT on Insomnia Severity Index, cancer related symptoms (fatigue&#xD;
      [Functional Assessment of Chronic Illness Therapy (FACIT-F) subscale, Edmonton Symptom&#xD;
      Assessment System (ESAS)], anxiety, depression anxiety [Hospital Anxiety Depression Scale&#xD;
      (HADS), ESAS]), quality of life (Functional Assessment of Cancer Therapy-General [FACT-G],&#xD;
      ESAS), and physical activity/sleep efficacy (actigraphy), before and after treatment with&#xD;
      various sleep disturbance (SD) treatment combinations of MMT.&#xD;
&#xD;
      II. To determine the safety of MMT (type, frequency, and severity of the adverse events).&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 8 treatment arms.&#xD;
&#xD;
      ARM I: Patients undergo CBT comprising 3 30-minute counseling sessions between baseline and&#xD;
      day 14. Patients also receive methylphenidate hydrochloride orally (PO) twice daily (BID) and&#xD;
      therapeutic melatonin PO once daily (QD), and undergo light therapy over 30 minutes for 15&#xD;
      days.&#xD;
&#xD;
      ARM II: Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO&#xD;
      BID and melatonin placebo PO QD, and undergo sham light therapy over 30 minutes for 15 days.&#xD;
&#xD;
      ARM III: Patients undergo CBT as in Arm I. Patients also receive methylphenidate&#xD;
      hydrochloride PO BID and therapeutic melatonin PO QD, and undergo sham light therapy over 30&#xD;
      minutes for 15 days.&#xD;
&#xD;
      ARM IV: Patients undergo CBT as in Arm I. Patients also receive methylphenidate hydrochloride&#xD;
      PO BID and melatonin placebo PO QD, and undergo light therapy over 30 minutes for 15 days.&#xD;
&#xD;
      ARM V: Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID&#xD;
      and therapeutic melatonin PO QD, and undergo light therapy over 30 minutes for 15 days.&#xD;
&#xD;
      ARM VI: Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO&#xD;
      BID and melatonin placebo PO QD, and undergo light therapy over 30 minutes for 15 days.&#xD;
&#xD;
      ARM VII: Patients undergo CBT as in Arm I. Patients also receive methylphenidate&#xD;
      hydrochloride PO BID and melatonin placebo PO QD, and undergo sham light therapy over 30&#xD;
      minutes for 15 days.&#xD;
&#xD;
      ARM VIII: Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO&#xD;
      BID and therapeutic melatonin PO QD, and undergo sham light therapy over 30 minutes for 15&#xD;
      days.&#xD;
&#xD;
      Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up on days 29 and 45.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 15, 2014</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pittsburgh Sleep Quality Index (PSQI) score</measure>
    <time_frame>Baseline up to day 29</time_frame>
    <description>Estimates of treatment effects and combinations of treatment effects will be obtained by using standard linear regression techniques in which the change in PSQI values are regressed on indicator variables that represent treatment combinations that received 3 main effects for the primary treatments, 3 two-way interaction terms for each combination of two treatments, and 1 three-way interaction effects, which will be included in the linear regression model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Insomnia Severity Index scores</measure>
    <time_frame>Baseline up to day 29</time_frame>
    <description>Exploratory data analyses to examine associations between patients' change in PSQI score and the secondary measure of Insomnia Severity Index. Multivariate regression analyses will also be performed to determine the predictive relationship of this variable on PSQI and change in PSQI scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Assessment of Chronic Illness Therapy (FACIT)-F scores</measure>
    <time_frame>Baseline up to day 29</time_frame>
    <description>Exploratory data analyses to examine associations between patients' change in PSQI score and the secondary measure of FACIT-F scores. Multivariate regression analyses will also be performed to determine the predictive relationship of this variable on PSQI and change in PSQI scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hospital Anxiety Depression Scale (HADS) scores</measure>
    <time_frame>Baseline up to day 29</time_frame>
    <description>Exploratory data analyses to examine associations between patients' change in PSQI score and the secondary measure of HADS scores. Multivariate regression analyses will also be performed to determine the predictive relationship of this variable on PSQI and change in PSQI scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Edmonton Symptom Assessment System (ESAS) scores</measure>
    <time_frame>Baseline up to day 29</time_frame>
    <description>Exploratory data analyses to examine associations between patients' change in PSQI score and the secondary measure of ESAS scores. Multivariate regression analyses will also be performed to determine the predictive relationship of this variable on PSQI and change in PSQI scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in actigraphy data</measure>
    <time_frame>Baseline up to day 15</time_frame>
    <description>Differences between participants receiving the MMT or the placebo treatment will be analyzed. This analysis will be based on fitting mixed effect linear models with actigraphy data as the response variables, and treatment intervention, demographic variables, and treatment site as independent variables.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 45 days</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Malignant Solid Neoplasm</condition>
  <condition>Sleep Disorder</condition>
  <arm_group>
    <arm_group_label>Arm I (methylphenidate, melatonin, light therapy, CBT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo CBT comprising 3 30-minute counseling sessions between baseline and day 14. Patients also receive methylphenidate hydrochloride PO BID and therapeutic melatonin PO QD, and undergo light therapy over 30 minutes for 15 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo, placebo, sham light therapy, CBT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID and melatonin placebo PO QD, and undergo sham light therapy over 30 minutes for 15 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (methylphenidate, melatonin, sham light therapy, CBT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo CBT as in Arm I. Patients also receive methylphenidate hydrochloride PO BID and therapeutic melatonin PO QD, and undergo sham light therapy over 30 minutes for 15 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV (methylphenidate, placebo, light therapy, CBT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo CBT as in Arm I. Patients also receive methylphenidate hydrochloride PO BID and melatonin placebo PO QD, and undergo light therapy over 30 minutes for 15 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm V (placebo, melatonin, light therapy, CBT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID and therapeutic melatonin PO QD, and undergo light therapy over 30 minutes for 15 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm VI (placebo, placebo, light therapy, CBT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID and melatonin placebo PO QD, and undergo light therapy over 30 minutes for 15 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm VII (methylphenidate, placebo, sham light therapy, CBT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo CBT as in Arm I. Patients also receive methylphenidate hydrochloride PO BID and melatonin placebo PO QD, and undergo sham light therapy over 30 minutes for 15 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm VIII (placebo, melatonin, sham light intervention, CBT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID and therapeutic melatonin PO QD, and undergo sham light therapy over 30 minutes for 15 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Counseling</intervention_name>
    <description>Undergo CBT</description>
    <arm_group_label>Arm I (methylphenidate, melatonin, light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm II (placebo, placebo, sham light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm III (methylphenidate, melatonin, sham light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm IV (methylphenidate, placebo, light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm V (placebo, melatonin, light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm VI (placebo, placebo, light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm VII (methylphenidate, placebo, sham light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm VIII (placebo, melatonin, sham light intervention, CBT)</arm_group_label>
    <other_name>Counseling Intervention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (methylphenidate, melatonin, light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm III (methylphenidate, melatonin, sham light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm IV (methylphenidate, placebo, light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm VII (methylphenidate, placebo, sham light therapy, CBT)</arm_group_label>
    <other_name>Concerta</other_name>
    <other_name>Quillivant XR</other_name>
    <other_name>Ritalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Phototherapy</intervention_name>
    <description>Undergo light therapy</description>
    <arm_group_label>Arm I (methylphenidate, melatonin, light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm IV (methylphenidate, placebo, light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm V (placebo, melatonin, light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm VI (placebo, placebo, light therapy, CBT)</arm_group_label>
    <other_name>Actinotherapy</other_name>
    <other_name>Bright Light Therapy</other_name>
    <other_name>light therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Administration</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (placebo, placebo, sham light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm IV (methylphenidate, placebo, light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm V (placebo, melatonin, light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm VI (placebo, placebo, light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm VII (methylphenidate, placebo, sham light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm VIII (placebo, melatonin, sham light intervention, CBT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (methylphenidate, melatonin, light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm II (placebo, placebo, sham light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm III (methylphenidate, melatonin, sham light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm IV (methylphenidate, placebo, light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm V (placebo, melatonin, light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm VI (placebo, placebo, light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm VII (methylphenidate, placebo, sham light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm VIII (placebo, melatonin, sham light intervention, CBT)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham Intervention</intervention_name>
    <description>Undergo sham light therapy</description>
    <arm_group_label>Arm II (placebo, placebo, sham light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm III (methylphenidate, melatonin, sham light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm VII (methylphenidate, placebo, sham light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm VIII (placebo, melatonin, sham light intervention, CBT)</arm_group_label>
    <other_name>Sham Comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Therapeutic Melatonin</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (methylphenidate, melatonin, light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm III (methylphenidate, melatonin, sham light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm V (placebo, melatonin, light therapy, CBT)</arm_group_label>
    <arm_group_label>Arm VIII (placebo, melatonin, sham light intervention, CBT)</arm_group_label>
    <other_name>Circadin</other_name>
    <other_name>Melatonin</other_name>
    <other_name>Melaxen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cancer patients currently on cancer therapy with a positive screening for SD&#xD;
             (screening PSQI score &gt;= 5)&#xD;
&#xD;
          -  Patients should have a Zubrod =&lt; 2&#xD;
&#xD;
          -  Patients with no pain and with stable pain (defined as pain under control and on&#xD;
             stable doses of opioids for 1 week) are eligible&#xD;
&#xD;
          -  Memorial delirium assessment scale =&lt; 13&#xD;
&#xD;
          -  Controlled pain and depression symptoms, if present (defined as no change in the&#xD;
             morphine equivalent dose of 30% or change in the dose of antidepressant medication in&#xD;
             the past 2 weeks)&#xD;
&#xD;
          -  All patients who are receiving chemotherapy and/or radiation therapy are eligible for&#xD;
             study if they have completed &gt; 1 week of radiation therapy, and if they have been&#xD;
             approved to go on study by their primary oncologist; the principal investigator&#xD;
             (PI)/designated research staff of this study will obtain and document approval from&#xD;
             the primary oncologist and principal investigator of the clinical trial in case the&#xD;
             patient is on another clinical trial as referenced in the patient's study documents&#xD;
&#xD;
          -  Serum creatinine =&lt; 2.0 mg/dL&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 mg/dL&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and&#xD;
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 2 x&#xD;
             upper limit of normal (ULN) or =&lt; 5 x ULN if hepatic metastases are present&#xD;
&#xD;
          -  Patients on stable doses (defined as same dose for 2 weeks) of dexamethasone,&#xD;
             mirtazapine, zolpidem, benzodiazepines, phenothiazines are allowed to participate in&#xD;
             the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a major contraindication to methylphenidate (MP) (e.g., allergy/hypersensitivity&#xD;
             to study medications or their constituents), light therapy (e.g., currently receiving&#xD;
             ultraviolet A [UVA]/ultraviolet B [UVB] therapy), cognitive behavioral therapy (e.g.,&#xD;
             schizophrenia), or conditions making adherence difficult as determined by the&#xD;
             attending physician&#xD;
&#xD;
          -  Currently taking MP or have taken it within the previous 10 days&#xD;
&#xD;
          -  Patients with a diagnosis of polysomnographically confirmed obstructive sleep apnea or&#xD;
             narcolepsy&#xD;
&#xD;
          -  Regularly used cognitive behavioral therapy in the last 6 weeks for sleep disturbance&#xD;
&#xD;
          -  Unable to complete the baseline assessment forms or to understand the recommendations&#xD;
             for participation in the study&#xD;
&#xD;
          -  Currently with a diagnosis of major depression, manic depressive disorder,&#xD;
             obsessive-compulsive disorder, or schizophrenia)&#xD;
&#xD;
          -  Need monoamine oxidase inhibitors, tricyclic antidepressants, or clonidine&#xD;
&#xD;
          -  Have glaucoma&#xD;
&#xD;
          -  Symptomatic tachycardia and uncontrolled hypertension (determined to be clinically&#xD;
             significant by the PI)&#xD;
&#xD;
          -  Currently receiving anticonvulsants (phenobarbital, diphenylhydantoin, primidone),&#xD;
             phenylbutazone, clonidine, and/or tricyclic drugs (imipramine, clomipramine, or&#xD;
             desipramine)&#xD;
&#xD;
          -  Unable to speak and understand English&#xD;
&#xD;
          -  Persons with congenital blindness and self-reported acquired blindness (independent of&#xD;
             the cause) with no light perception&#xD;
&#xD;
          -  Patients with a history of retinal disease&#xD;
&#xD;
          -  Patients with &gt; 2 hours of direct exposure to outdoor natural light per day by&#xD;
             interview with the Study Coordinator&#xD;
&#xD;
          -  Patients with a diagnosis of obesity hypoventilation syndrome&#xD;
&#xD;
          -  Positive pregnancy test for women of childbearing potential, as defined by intact&#xD;
             uterus and ovaries, and a history of menses within the last 12 months; pregnancy test&#xD;
             to be performed no greater than 14 days prior to consent in study; in cases of women&#xD;
             with elevated beta (b)-human chorionic gonadotropin (HCG), these candidates will be&#xD;
             eligible to participate so long as the level of b-HCG is not consistent with&#xD;
             pregnancy; women of childbearing potential need to be on or use contraception, or be&#xD;
             abstinent during the study period; their male partners must also use contraception&#xD;
             (condom) or maintain abstinence; birth control specifications: women who are able to&#xD;
             become pregnant must use birth control during the study and for 30 days after&#xD;
&#xD;
          -  Women who are nursing&#xD;
&#xD;
          -  Patients who have taken melatonin within the past two weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sriram Yennu</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 22, 2012</study_first_submitted>
  <study_first_submitted_qc>June 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2012</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Dyssomnias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

